Charles River Laboratories wraps up $380m acquisition of HemaCare

This article was originally published here

As per the deal announced in December 2019, Charles River Laboratories offered to buy HemaCare for $25.40 per share. The California-based company, which will now operate under Charles

The post Charles River Laboratories wraps up $380m acquisition of HemaCare appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply